本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 | 证券代码：603538 | 证券简称：美诺华 | 公告编号：2024-048 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 第五届监事会第一次会议决议公告 宁波美诺华药业股份有限公司 监事会 2024 年 5 月 21 日 报备文件： 宁波美诺华药业股份有限公司（以下简称"公司"）第五届监事会第一次会 议于 2024 年 5 月 20 日在公司会议室以现场表决方式召开。本次会议由刘斯斌先 生主持，会议应出席监事 3 名，实际出席监事 3 名。公司董事会秘书应高峰先生 列席会议。本次会议的召集和召开符合《中华人民共和国公司法》等有关法律法 规及《公司章程》的规定。 二、监事会会议审议情况 1、审议通过《关于选举第五届监事会主席的议案》 选举刘斯斌先生担任公司第五届监事会主席，任期与本届监事会一致。 表决结果：同意 3 票，反对 0 票，弃权 0 票。 特此公告。 1、《 ...

| 证券代码：603538 | 证券简称：美诺华 | 公告编号：2024-047 | | --- | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | | 宁波美诺华药业股份有限公司 第五届董事会第一次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 宁波美诺华药业股份有限公司（以下简称"公司"）第五届董事会第一次会 议于 2024 年 5 月 20 日在公司会议室以现场表决方式召开。本次会议由姚成志先 生主持，会议应出席董事 5 名，实际出席董事 5 名。公司监事、高级管理人员列 席了会议。本次会议的召集和召开符合《中华人民共和国公司法》等有关法律法 规及《公司章程》《董事会议事规则》的规定。 选举姚成志先生担任公司第五届董事会董事长，任期自董事会通过之日起至 第五届董事会届满之日止 表决结果：同意 5 票，反对 0 票，弃权 0 票。 2、审议通过《关于选举公司第五届董事会专门委员会委员的议案》》 公司第五届董事会下设战略委员会、审计委员会、薪酬与考核委员会 ...

上海市广发律师事务所 关于宁波美诺华药业股份有限公司 2023 年年度股东大会的 法律意见书 电话：021-58358013 | 传真：021-58358012 网址：http://www.gffirm.com | 电子信箱：gf@gffirm.com 办公地址：上海市浦东新区南泉北路 429 号泰康保险大厦 26 楼 | 邮政编码：200120 上海市广发律师事务所 关于宁波美诺华药业股份有限公司 2023 年年度股东大会的法律意见书 致：宁波美诺华药业股份有限公司 宁波美诺华药业股份有限公司（以下简称"公司"）2023 年年度股东大会 于 2024 年 5 月 20 日（星期一）在浙江省宁波市高新区扬帆路 999 弄研发园 B1 号楼 12A 层 1 号会议室召开。上海市广发律师事务所经公司聘请，委派姚思静 律师、姚培琪律师出席现场会议。根据《中华人民共和国公司法》（以下简称"《公 司法》"）、《上市公司股东大会规则（2022 年修订）》（以下简称"《股东 大会规则》"）等法律法规、其他规范性文件以及《宁波美诺华药业股份有限公 司章程》（以下简称"《公司章程》"）的规定，就本次股东大会的召集和召开 程序、 ...

| 证券代码：603538 | 证券简称：美诺华 公告编号：2024-046 | | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | 宁波美诺华药业股份有限公司 2023 年年度股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次会议是否有否决议案：无 一、会议召开和出席情况 （一）股东大会召开的时间：2024 年 5 月 20 日 （二）股东大会召开的地点：浙江省宁波市高新区扬帆路 999 弄研发园 B1 号楼 12A 层 1 号会议室。 （三）出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席会议的股东和代理人人数 | 33 | | --- | --- | | 2、出席会议的股东所持有表决权的股份总数（股） | 62,161,893 | | 3、出席会议的股东所持有表决权股份数占公司有表决权股份 | 29.1358 | | 总数的比例（%） | | （四）表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会 ...

宁波美诺华药业股份有限公司 2023 年年度股东大会会议资料 宁波美诺华药业股份有限公司 2023 年年度股东大会会议资料 | 会 议 议 程 4 | | | --- | --- | | 会 议 须 知 6 | | | 议案一 7 | | | 年度董事会工作报告 2023 7 | | | 议案二 16 | | | 年度监事会工作报告 2023 16 | | | 议案三 22 | | | 年年度报告及摘要 2023 22 | | | 议案四 23 | | | 年度财务决算报告 | 2023 23 | | 议案五 25 | | | 议案六 26 | | | 议案七 27 | | | 关于授权董事长办理融资事宜的议案 27 | | | 议案八 28 | | | 关于为子公司融资提供担保的议案 28 | | | 议案九 33 | | | 关于使用闲置募集资金进行现金管理的议案 33 | | | 议案十 36 | | | 关于使用闲置自有资金进行现金管理的议案 36 | | | 议案十一 38 | | | 关于 年度公司董事、监事及高级管理人员薪酬方案的议案 2024 38 | | | 议案十二 39 | | | 关于 ...

宁波美诺华药业股份有限公司 投资者关系活动记录表 √特定对象调研 □分析师会议 □媒体采访 □业绩说明会 投资者关系活动类别 □新闻发布会 □路演活动 □现场参观 □其他 太平洋证券、中泰证券、方正证券、华创证券、兴业证券、光大证 券、平安证券、东吴证券、上海域秀资产管理有限公司、大成基金 管理有限公司、东海证券有限责任公司、深圳市翼虎投资管理有限 公司、中银基金管理有限公司、永赢基金、北京泓澄投资管理有限 公司、平安资产管理有限责任公司、国信证券证券投资部、安信基 金管理有限责任公司、敦和资产管理有限公司、宁波三登投资管理 合伙企业（有限合伙）、上海水璞、华创自营、华泰证券责任有限 参与单位名称 公司（自营）、新柏霖、中国人寿养老保险股份有限公司、景顺长 城、中银国际证券股份有限公司、格林基金管理有限公司、北京琮 碧秋实私募基金管理有限公司、长盛基金管理有限公司、明亚基金 管理有限责任公司、华宝基金管理有限公司、怀信资本、太平洋寿 ...

Financial Performance - The company's operating revenue for Q1 2024 was ¥262,766,361.43, representing a year-on-year increase of 6.68%[3] - The net profit attributable to shareholders decreased by 67.68% to ¥14,043,259.71 compared to the same period last year[3] - The net profit attributable to shareholders after deducting non-recurring gains and losses increased by 72.63% to ¥20,527,312.45[3] - The basic earnings per share decreased by 66.67% to ¥0.07, while diluted earnings per share decreased by 65.00% to ¥0.07[3] - Operating profit for Q1 2024 decreased to RMB 21,690,375.36, down 61.3% from RMB 56,064,797.51 in Q1 2023[21] - In Q1 2024, the company reported a net profit of ¥15,770,884.38, a decrease of 65.9% compared to ¥46,218,606.15 in Q1 2023[22] - The total comprehensive income for Q1 2024 was ¥15,789,457.91, compared to ¥45,470,205.48 in the same quarter last year, a decrease of 65.3%[22] Assets and Liabilities - The total assets at the end of the reporting period were ¥4,344,246,476.68, a decrease of 1.79% from the end of the previous year[3] - Total assets as of March 31, 2024, were RMB 4,344,246,476.68, a slight decrease from RMB 4,423,515,920.66 as of December 31, 2023[18] - Total liabilities decreased to RMB 2,142,290,717.71 as of March 31, 2024, from RMB 2,237,831,964.82 as of December 31, 2023, a reduction of 4.3%[19] - The company’s total liabilities increased, with cash outflows for debt repayment amounting to ¥181,966,366.36, compared to ¥107,526,000.00 in the previous year[26] Cash Flow - The net cash flow from operating activities was negative at -¥54,422,979.34, primarily due to increased payments for goods[3] - The net cash flow from operating activities was -¥54,422,979.34, worsening from -¥16,639,241.51 in Q1 2023[25] - Cash and cash equivalents as of March 31, 2024, were RMB 351,891,745.57, down from RMB 456,042,013.93 as of December 31, 2023, a decrease of 22.8%[18] - Cash and cash equivalents at the end of Q1 2024 were ¥231,088,104.66, down from ¥468,943,485.90 at the end of Q1 2023[26] - Investment activities resulted in a net cash outflow of -¥25,327,096.38, an improvement from -¥101,092,484.23 in Q1 2023[26] - The company reported cash inflows from financing activities of ¥218,932,991.66, an increase from ¥138,468,439.40 in Q1 2023[26] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 30,742[8] - The largest shareholder, Ningbo Meinuohua Holding Group Co., Ltd., held 21.22% of the shares, totaling 45,273,661 shares[9] - As of March 31, 2024, Ningbo Meinuo Holdings Group Co., Ltd. holds 45,273,661 shares, representing 21.22% of total shares[10] - The top 10 shareholders include Ningbo Meinuo Holdings Group Co., Ltd. and several individual shareholders, with the largest individual shareholder holding 12,070,253 shares[10] Research and Development - Research and development expenses increased by 36.67%, indicating an increase in formulation R&D projects[7] - Research and development expenses increased to RMB 15,827,004.16 in Q1 2024, compared to RMB 11,580,047.95 in Q1 2023, representing a rise of 36.5%[21] Investment and Foreign Exchange - The company reported a significant decrease in investment income by 150.21%, mainly due to losses from foreign exchange derivatives trading[7] - The company reported a loss of -2,355.76 million USD from foreign exchange derivatives, with a fair value change of 736.63 million USD during the reporting period[13] - The nominal amount of USD forward foreign exchange contracts is 4,210 million USD, with an average exchange rate of 6.8266 for the contracts[15] - The company engaged in foreign exchange hedging to mitigate risks associated with currency fluctuations, enhancing financial stability[13] Miscellaneous - The report indicates no significant changes in accounting policies or practices compared to the previous reporting period[13] - The company has not reported any ongoing litigation as of the latest quarter[14] - The total amount of shares lent through the securities lending program is 12,000 shares[12] - The company’s cash flow hedging tools include selling USD forward contracts with varying maturities[15] - The report does not include any audit opinion type, indicating it is not applicable for this quarter[16]

上海证券交易所文件 上证上审（再融资）〔2024〕99 号 关于终止对宁波美诺华药业股份有限公司 向特定对象发行股票审核的决定 宁波美诺华药业股份有限公司： 上海证券交易所（以下简称本所）于 2023 年 8 月 24 日 依法受理了你公司向特定对象发行股票的申请文件，并按照 规定进行了审核。 2024 年 4 月 19 日，你公司和保荐人万联证券股份有限 公司向本所提交了《宁波美诺华药业股份有限公司关于撤回 2023 年度向特定对象发行股票申请文件的申请》和《万联证 券股份有限公司关于撤销宁波美诺华药业股份有限公司 2023 年度向特定对象发行股票保荐的申请》，分别申请撤回 向特定对象发行股票的申请文件和申请撤销向特定对象发 行股票并在主板上市保荐工作。根据《上海证券交易所上市 - 1 - ─────────────── 公司证券发行上市审核规则》第十九条、《上海证券交易所 股票发行上市审核规则》第六十三条（二）的有关规定，本 所决定终止对你公司向特定对象发行股票的审核。 上海证券交易所 二〇二四年四月二十八日 主题词：主板 再融资 终止通知 上海证券交易所 2024 年 04 月 28 日印发 - 2 - ...

Financial Performance - The company's operating revenue for 2023 was CNY 1,216,499,285.68, a decrease of 16.51% compared to the previous year[23]. - The net profit attributable to shareholders for 2023 was CNY 11,585,592.13, reflecting a significant decline of 96.58% year-on-year[23]. - The net profit after deducting non-recurring gains and losses was CNY 8,450,550.35, down 96.36% from the previous year[23]. - The net cash flow from operating activities was CNY 9,133,098.81, a decrease of 96.70% compared to the previous year[23]. - The company's total assets at the end of 2023 were CNY 4,423,515,920.66, a slight increase of 0.09% from the previous year[23]. - The net assets attributable to shareholders at the end of 2023 were CNY 2,096,251,882.49, an increase of 0.54% year-on-year[23]. - The basic earnings per share for 2023 were CNY 0.05, down 96.89% from CNY 1.61 in 2022[24]. - The weighted average return on equity for 2023 was 0.56%, a decrease of 17.02 percentage points from the previous year[24]. - The company reported a quarterly revenue of CNY 287,965,636.10 in Q4 2023, with a net profit attributable to shareholders of -CNY 42,952,820.42[27]. - The overall gross margin for the main business was 31.01%, a decrease of 9.29 percentage points year-on-year[70]. Dividend and Shareholder Information - The company plans to distribute a cash dividend of 0.02 CNY per share (including tax) based on the total share capital registered on the dividend distribution date[6]. - The total number of shares held by Chairman and General Manager Yao Chengzhi remained unchanged at 12,070,253 shares[150]. - CFO Ying Gaofeng increased his shareholding by 3,352 shares due to option exercise, bringing his total to 98,349 shares[150]. - The total pre-tax compensation for Yao Chengzhi was 609,500 RMB, while Ying Gaofeng received 267,000 RMB[150]. - The company has a total of 268.42 million shares held by directors and supervisors[150]. - The company plans to implement a shareholder return plan for the years 2023-2025[159]. - The company has a cash dividend policy that complies with its articles of association and shareholder resolutions[173]. Audit and Compliance - The company has received a standard unqualified audit report from Lixin Certified Public Accountants[5]. - The company has confirmed that more than half of the directors can guarantee the authenticity, accuracy, and completeness of the annual report[8]. - The company has not faced any situations that would lead to stock suspension or delisting risk warnings[8]. - The company has not violated decision-making procedures for external guarantees[8]. - The supervisory board strictly performed its duties in accordance with the company's articles of association and relevant regulations, ensuring the legality and compliance of the management's actions[141]. - The management team adhered to the company's articles of association and did not exceed their authority, submitting all matters beyond their scope to the board for review[143]. - The company maintained strict compliance with information disclosure regulations, ensuring timely and accurate reporting to all shareholders[143]. - The company reported no penalties from securities regulatory agencies in the past three years[158]. Research and Development - The R&D team consists of 633 personnel, showing a year-on-year increase of 6.6%, enhancing the company's research capabilities[59]. - The company has submitted 25 patent applications and received 17 patents during the reporting period, including 7 invention patents[97]. - The company's R&D investment for 2023 was CNY 137.52 million, an increase of 14.76% year-on-year, accounting for 11.30% of total revenue[97]. - The company is focusing on the chronic disease treatment sector, leveraging various technology platforms to develop high-value generics[54]. - The company is actively pursuing CDE reviews for multiple projects, indicating a robust pipeline and commitment to regulatory compliance[99]. - The company is currently developing multiple raw material drug projects, including Lenvatinib Mesylate for anti-tumor treatment, which is under CDE review[99]. - The company is advancing projects for treating epilepsy and has completed verification, preparing for CDE submission[99]. - The company is focusing on expanding its product pipeline with a variety of therapeutic areas, including anti-inflammatory and anti-viral drugs[99]. Market and Strategic Initiatives - The global pharmaceutical market is projected to reach $1.9 trillion by 2027, with China's therapeutic drug market expected to grow by 9.9% in 2023, reaching ¥1.86 trillion[44]. - The company aims to strengthen its CDMO business and expand upstream and downstream operations to enhance its industry chain layout[49]. - The company achieved significant results in centralized procurement, with successful bids for multiple products, enhancing market share and brand influence[37]. - The company is actively developing innovative medical products to support its strategic goals and drive future growth[49]. - The company is committed to sustainable development and aims to become a leading pharmaceutical enterprise in China by deepening its focus on niche markets[129]. Environmental and Social Responsibility - The company invested ¥57.89 million in environmental protection during the reporting period[184]. - The company achieved a total wastewater discharge of 99.63 tons/year for chemical oxygen demand, with an actual discharge of 55.92 tons/year, well below the permitted limit[185]. - The company reported a reduction of 7,118 tons in carbon emissions, implementing measures such as biogas boiler systems and waste heat recovery[193]. - Total donations amounted to 288,600 CNY, with 219,500 CNY in cash and 69,100 CNY in material donations[194]. - The company donated approximately 48,600 CNY worth of medical supplies to flood-affected areas in Hebei[194]. Risk Management - The company emphasizes quality control as a critical risk, with a commitment to enhance process management and adhere to international quality standards[132]. - The company faces market competition risks due to the entry of domestic and international competitors, prompting efforts to expand customer bases and develop new products[133]. - The company is exposed to foreign exchange risks, particularly with a high proportion of revenue from overseas markets priced in foreign currencies[133]. - The company has established stable relationships with key suppliers to mitigate risks related to raw material supply and price increases[134].

| 证券代码：603538 | 证券简称：美诺华 公告编号：2024-025 | | --- | --- | | 转债代码：113618 | 转债简称：美诺转债 | 宁波美诺华药业股份有限公司 关于全资子公司获得维格列汀片药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 宁波美诺华药业股份有限公司（以下简称"公司"）全资子公司宁波美诺华 天康药业有限公司（以下简称"美诺华天康"）于近日收到国家药品监督管理局 （以下简称"国家药监局"）核准签发的维格列汀片《药品注册证书》，现将相关 情况公告如下： 一、药品相关信息 1、药品名称：维格列汀片 11、审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查， 本品符合药品注册的有关要求，批准注册，发给药品注册证书。药品生产企业应 当符合药品生产质量管理规范要求方可生产销售。 二、药品的其他相关情况 药品适应症：治疗 2 型糖尿病;高血糖症;糖尿病前期。 2、剂型：片剂 3、规格：50mg 4、申请事项：药品注册（境内生产） 5、注册分类：化学药品 4 类 6、 ...